Key result
Phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol increased the risk of PCOS by 32% and 17% per 1 SD increase, respectively.
Why the study?
Specific lipid profiles associated with polycystic ovary syndrome vary across studies and observational data cannot establish causation.
Does phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol causally increase the risk of Polycystic Ovary Syndrome?
Observational
Does phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol causally increase the risk of Polycystic Ovary Syndrome?
Effect estimate: 32% increase in risk per 1 SD increase
Phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol are independent causal risk factors for PCOS, with the latter mediating part of the effect of the former.
BACKGROUND: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age, marked by hormonal imbalances and disruptions in glucose and lipid metabolism. Emerging research has indicated a correlation between lipids and PCOS, yet the specific lipid profiles or associated genes identified in various studies vary, and observational data alone cannot establish causation. Therefore, our study seeks to establish a causal association between lipidome and PCOS. METHODS: Data from genome-wide association studies, liposomes, metabolites, and PCOS-related information were collected. Four rounds of double-sample bidirectional intermediate Mendelian Randomization analyses including liposomes to disease, liposomes to metabolites, metabolites to disease, and reverse Mendelian Randomization analysis of lipids, total effect values and intermediary effect values were calculated. The proportion mediated by the intermediary effect was determined by dividing the intermediary effect value by the total effect value. RESULTS: The analyses revealed that three liposomes and nine metabolites were causally associated with PCOS. Specifically, phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol were identified as independent risk factors for PCOS through further Mendelian Randomization analysis. The risk of developing PCOS increased by 32% for every one standard deviation increase in phosphatidylcholine and by 17% for every one standard deviation increase in 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol. Furthermore, the study revealed that phosphatidylcholine can influence the development of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol acting as a mediator, explaining 4.97% of the effect. CONCLUSIONS: This study confirmed a causal relationship between phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol with PCOS, where phosphatidylcholine can influence the occurrence of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol as a mediator.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2024) conducted an observational in Polycystic ovary syndrome (PCOS). Phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol was evaluated on Risk of developing PCOS (32% increase in risk per 1 SD increase). Phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol increased the risk of PCOS by 32% and 17% per 1 SD increase, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: